# CT to Assess the Efficacy and Safety of Adding GMA to Infliximab in Paediatric Patients With Steroid-refractory Ulcerative Colitis

> **NCT05430412** · NA · UNKNOWN · sponsor: **Adacyte Therapeutics SL** · enrollment: 15 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DEVICE:** Adacolumn

## Key facts

- **NCT ID:** NCT05430412
- **Lead sponsor:** Adacyte Therapeutics SL
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-11
- **Primary completion:** 2024-10
- **Final completion:** 2024-10
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-01-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05430412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05430412, "CT to Assess the Efficacy and Safety of Adding GMA to Infliximab in Paediatric Patients With Steroid-refractory Ulcerative Colitis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05430412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*